Háskóli ÍslandsUniversity of IcelandDovey de la Cour, CecilieGuleria, SoniaNygård, MariTryggvadottir, LaufeySigurdsson, KristjanLiaw, KailiHortlund, MariaLagheden, CamillaHansen, Bo TerningMunk, ChristianDillner, JoakimKjaer, Susanne K.2020-05-182020-05-182019-01-11Dovey de la Cour, C, Guleria, S, Nygård, M, et al. Human papillomavirus types in cervical high‐grade lesions or cancer among Nordic women—Potential for prevention. Cancer Medicine. 2019; 8: 839– 849. https://doi.org/10.1002/cam4.19612045-7634https://hdl.handle.net/20.500.11815/1811Publisher's version (útgefin grein)It is valuable to establish a population‐based prevaccination baseline distribution of human papillomavirus (HPV) types among women with high‐grade cervical intraepithelial neoplasia (CIN) grade 2 or 3 and cervical cancer in order to assess the potential impact of HPV vaccination. In four countries (Denmark, Norway, Sweden, and Iceland), we collected consecutive series of cervical cancers (n = 639) and high‐grade precancerous cervical lesions (n = 1240) during 2004‐2006 before implementation of HPV vaccination and subjected the specimens to standardized HPV genotyping. The HPV prevalence was 82.7% (95% confidence interval [CI] 79.0‐86.4) in CIN2, 91.6% (95% CI 89.7‐93.5) in CIN3, and 86.4% (95% CI 83.7‐89.1) in cervical cancer. The most common HPV types in CIN2/3 were HPV16 (CIN2: 35.9%, 95% CI 31.2‐40.6; CIN3: 50.2%, 95% CI 46.8‐53.6) and HPV31 (CIN2: 10.9%, 95% CI 7.8‐13.9; CIN3: 12.1%, 95% CI 9.9‐14.3), while HPV16 and HPV18 were the most frequent types in cervical cancer (48.8%, 95% CI 44.9‐52.7 and 15.3%, 95% CI 12.5‐18.1, respectively). The prevalence of HPV16/18 decreased with increasing age at diagnosis in both CIN2/3 and cervical cancer (P < 0.0001). Elimination of HPV16/18 by vaccination is predicted to prevent 42% (95% CI 37.0‐46.7) of CIN2, 57% (95% CI 53.8‐60.5) of CIN3 and 64% (95% CI 60.3‐67.7) of cervical cancer. Prevention of the five additional HPV types HPV31/33/45/52/58 would increase the protection to 68% (95% CI 63.0‐72.2) in CIN2, 85% (95% CI 82.4‐87.2) in CIN3 and 80% (95% CI 77.0‐83.2) in cervical cancer. This study provides large‐scale and representative baselines for assessing and evaluating the population‐based preventive impact of HPV vaccination.839-849eninfo:eu-repo/semantics/openAccessCervical cancerCervical intraepithelial neoplasiaHuman papillomavirusNordic countriesPrevalenceLeghálskrabbameinVeirurTíðniNorðurlöndinfo:eu-repo/semantics/articleCancer Medicine10.1002/cam4.1961